The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes

QR Code

The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes

Gliclazide (G) is used to treat type 2 diabetes (T2D), and also has anti-platelet, anti-radical, and anti-inflammatory effects. G has poor water solubility and high inter-individual variations in absorption, limiting its application in type 1 diabetes (T1D). The bile acid, chenodeoxycholic acid (CDC...

Full description

Bibliographic Details
Main Authors:	Mathavan, S., Chen-Tan, N., Arfuso, Frank, Al-Salami, H.
Format:	Journal Article
Published:	2015
Online Access:	http://hdl.handle.net/20.500.11937/17577

Similar Items

Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid
by: Mathavan, S., et al.
Published: (2018)

The applications of microencapsulated formulation of gliclazide and bile acids in Type-1 diabetes mellitus
by: Mathavan, Sangeetha
Published: (2017)

A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes
by: Mathavan, Sangeetha, et al.
Published: (2015)

Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics
by: Mikov, M., et al.
Published: (2017)

Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats
by: Al-Salami, Hani, et al.
Published: (2012)

Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes
by: Negrulj, R., et al.
Published: (2015)

Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics
by: Al-Salami, Hani, et al.
Published: (2008)

Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine ß-cell Survival and the Inflammatory Response
by: Mooranian, A., et al.
Published: (2016)

The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes
by: Mooranian, Armin, et al.
Published: (2016)

Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System
by: Negrulj, Rebecca, et al.
Published: (2013)

An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations
by: Mooranian, A., et al.
Published: (2015)

Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study
by: Mooranian, A., et al.
Published: (2015)

Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects
by: Mathavan, S., et al.
Published: (2017)

Bile acid-based micro/nano capsules for the targeted oral delivery of probucol
by: Wagle, Susbin Raj
Published: (2020)

Bile acids and probiotics could help treating diabetes
by: Calasan, J., et al.
Published: (2012)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment
by: Mooranian, Armin, et al.
Published: (2015)

Application of bile acids in drug formulation and delivery
by: Stojancevic, M., et al.
Published: (2014)

The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study
by: Mooranian, A., et al.
Published: (2015)

Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics
by: Mooranian, Armin, et al.
Published: (2014)

Pharmacokinetic and Drug Absorption Profiles of the Anti-Hyperglycaemic Agent Gliclazide in Oral Tissue-Targeted Microcapsules in Rats
by: Jovic, Jelena, et al.
Published: (2020)

Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
by: Mooranian, Armin, et al.
Published: (2014)

Advanced bile acid-based multi-compartmental microencapsulated pancreatic ß-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.
by: Mooranian, A., et al.
Published: (2014)

Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
by: Mooranian, Armin, et al.
Published: (2014)

The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus
by: Woodhams, L., et al.
Published: (2017)

Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes
by: Mooranian, Armin, et al.
Published: (2014)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment (vol 32, pg 151, 2014)
by: Mooranian, A., et al.
Published: (2015)

A review on the formulation and analysis of anti-diabetic agent: Gliclazide
by: Helal Uddin, A.B.M., et al.
Published: (2013)

High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect
by: Golocorbin-Kon, S., et al.
Published: (2017)

Novel artificial cell microencapsulation of probucol and bile acids in diabetes mellitus
by: Mooranian, Armin
Published: (2018)

Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes
by: Mooranian, Armin, et al.
Published: (2018)

The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable ß-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies.
by: Mooranian, A., et al.
Published: (2015)

Designing anti-diabetic ß-cells microcapsules using polystyrenic sulfonate, polyallylamine and a tertiary bile acid: Morphology, bioenergetics and cytokine analysis.
by: Mooranian, A., et al.
Published: (2016)

Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats
by: Al-Salami, Hani, et al.
Published: (2009)

Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus
by: Wong, Chun Yuen, et al.
Published: (2018)

THE EFFECT OF BILE ACID SALT SODIUM 3ALPHA, 7ALPHA-DIHYDROXY-12-KETO-5BETA-CHOLANATE (MKC) AND PROBIOTIC PRETREATMENT ON GLICLAZIDE PERMEATION IN ILEAL TISSUES FROM HEALTHY AND DIABETIC RATS
by: Mikov, M., et al.
Published: (2014)

Bile salt chenodeoxycholate suppresses normal platelet functions through cyclic amp activation pathway
by: Metharom, Pat, et al.
Published: (2015)

Influence of the concentration of chenodeoxycholic acid on the performance of the N719 dye
by: Najm, A. S., et al.
Published: (2022)

An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer
by: Mooranian, Armin, et al.
Published: (2014)

Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles
by: Pavlovic, N., et al.
Published: (2018)

Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment
by: Wong, C., et al.
Published: (2017)

Cannot write session to /tmp/vufind_sessions/sess_croc3lp020894kjs8oo0q0el3a